Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Neurodegeneration Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CLU drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CLU/Clusterin ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native heterodimer glycosylation. |
View CLU Products |
| Gene Delivery | CLU Promise-ORF / Lentivirus Full-length ORF for stable cell lines and functional overexpression assays. |
View CLU Products |
| Benchmark Ab | Anti-CLU Recombinant Antibody Recombinant positive control derived from benchmark therapeutic sequences. |
View CLU Products |
| Validator | CLU siRNA Set For target knockdown verification and specificity profiling. |
View CLU Products |
| Related Target A | APP (Amyloid Beta Precursor Protein) Synergistic target in neurodegenerative disease pathology and clearance pathways. |
View APP Products |
| Related Target B | AKT1 Crucial downstream survival node; CLU overexpression mediates resistance via AKT pathway activation. |
View AKT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Preserving Native Heterodimeric Glycosylation | HEK293 mammalian expression ensures correct alpha/beta chain cleavage and complex carbohydrate post-translational modifications. |
| Differentiating sCLU vs nCLU isoforms | Sequence-verified extracellular domain (ECD) constructs specifically isolate the secretory chaperone isoform. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live CLU R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CLU therapeutics is intensifying, with major players shifting focus from traditional antisense oligonucleotides (ASOs) to monoclonal antibodies and targeted siRNA delivery. As first-generation therapies reach the clinic, the next wave of R&D is targeting the protein's chaperone function in cancer drug resistance and its role in amyloid-beta clearance in Alzheimer's Disease.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Academic Institutes, Biotech Startups | Solid Tumors, Metastasis | Epitope mapping and binding affinity (Need native heterodimeric CLU antigen) |
| siRNA / ASO | Alnylam, Ionis Partners | Prostate Cancer, Cardiometabolic | Knockdown validation (Need verified siRNA and Lentivirus for stable lines) |
| Small Molecule Chaperone Inhibitors | Pharma Innovators | Alzheimer's Disease, Proteostasis | Aggregation assays (Need high-purity, endotoxin-controlled recombinant CLU) |